ArticleFrontiers in oncology2023

FOLFIRI-bevacizumab as a second-line treatment for advanced biliary tract cancer after gemcitabine-based chemotherapy.

Nicolas Roussot et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.